Patience will run out for some investors. 2-73 has some promise but our clinical trials have not been definitively successful compared to the pre-clinical support. But that's not uncommon in biotech. (And why investors don't put more than 5% of their investment portfolio in it.) And we still have potential paths to approval.
There's a lot of foolish speculation here and it doesn't end well. Folks have to be careful.
News 
Market Data 
Discover 
